Skip to main content

Peer Review reports

From: Volasertib as a monotherapy or in combination with azacitidine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia: summary of three phase I studies

Original Submission
13 Jan 2022 Submitted Original manuscript
27 Jan 2022 Author responded Author comments - Uwe Platzbecker
Resubmission - Version 2
27 Jan 2022 Submitted Manuscript version 2
8 Feb 2022 Reviewed Reviewer Report
14 Feb 2022 Reviewed Reviewer Report - Tristan Knight
30 Mar 2022 Author responded Author comments - Uwe Platzbecker
Resubmission - Version 3
30 Mar 2022 Submitted Manuscript version 3
6 Apr 2022 Reviewed Reviewer Report - Tristan Knight
9 Apr 2022 Reviewed Reviewer Report
26 Apr 2022 Author responded Author comments - Uwe Platzbecker
Resubmission - Version 4
26 Apr 2022 Submitted Manuscript version 4
Publishing
29 Apr 2022 Editorially accepted
21 May 2022 Article published 10.1186/s12885-022-09622-0

You can find further information about peer review here.

Back to article page